18
Participants
Start Date
May 14, 2021
Primary Completion Date
October 31, 2023
Study Completion Date
October 31, 2023
LVGN6051
Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Pembrolizumab
Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Shanghai Chest Hospital, Shanghai
Lyvgen Biopharma Holdings Limited
INDUSTRY